Protocol Snapshot

Quick reference before the deep dive

Verified Vendors

LL-37

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Standard Dose

100–200mcg

Once daily by subcutaneous injection.

Cycle Length

2–6 weeks

2–4 weeks for acute support; 4–6 weeks for chronic issues.

Class

Cathelicidin

Review the full protocol details below.

Primary Use

Immune Support

Review the full protocol details below.

Peptide Grade

GradeC

LL-37 pairs broad antimicrobial biology with controlled topical wound-healing data, but inflammatory, autoimmune, and injectable-safety uncertainty limits the grade.

Research Community Safety

Foundation

Research context, mechanisms, and practical use cases

What is LL-37?

LL-37 is the only cathelicidin antimicrobial peptide produced by the human body. It is a 37-amino-acid peptide that serves as one of the innate immune system’s primary defenses against bacteria, viruses, fungi, and certain parasites. Its name reflects its structure: it begins with two leucine amino acids, represented by “LL,” and contains 37 amino acids.

The body produces LL-37 from a precursor protein called hCAP-18, or human cationic antimicrobial protein 18 kDa. When the immune system detects a threat, enzymes cleave hCAP-18 and release active LL-37. This occurs in neutrophils, macrophages, dendritic cells, natural killer cells, and epithelial cells throughout the body, particularly in the skin, lungs, and gastrointestinal tract.

LL-37 is unusually versatile. It can disrupt microbial membranes, modulate immune signaling, neutralize bacterial toxins, support wound repair, and stimulate angiogenesis. Because it acts through multiple pathways at once, pathogens may have more difficulty developing resistance to it than they do to many conventional antibiotics.

LL-37 has gained significant attention as antimicrobial resistance becomes a growing global health concern. Rather than acting only as a direct antimicrobial agent, it works as part of the body’s own immune-defense network. Clinical research has also tested topical LL-37 in wound-healing settings, including venous leg ulcers and diabetic foot ulcers.

LL-37 Benefits

Broad-Spectrum Antimicrobial Activity

LL-37 has demonstrated activity against gram-positive bacteria, gram-negative bacteria, fungi, and several enveloped viruses. Research has reported activity across dozens of bacterial, fungal, and viral species.

Biofilm Disruption

LL-37 can penetrate and disrupt biofilm structures, helping expose protected bacteria to immune clearance and antimicrobial treatment.

Wound Healing

Topical clinical research has shown accelerated wound closure through keratinocyte migration, re-epithelialization, angiogenesis, and simultaneous antimicrobial protection.

Immune Modulation

LL-37 supports pathogen clearance while also helping regulate inflammatory signaling and neutralize bacterial toxins that can drive excessive immune activation.

Synergy With Antibiotics

Laboratory studies suggest LL-37 can work synergistically with beta-lactam antibiotics and vancomycin by disrupting bacterial membranes and improving antibiotic access.

Endotoxin Neutralization

LL-37 can bind and neutralize lipopolysaccharide, the endotoxin released by gram-negative bacteria. Animal models have associated this effect with lower inflammatory signaling and endotoxin burden.

Protocol Planning

Dosing, cycling, and preparation

LL-37 Dosing Protocol

Standard Protocol

Dose

100 to 200mcg per day

Frequency

Once daily

Timing

No specific timing requirements

Route

Subcutaneous injection

Cycle

Acute Support

2 to 4 weeks

Chronic Issues

4 to 6 weeks

Starting Point

Begin at the lower end of the range and assess response before increasing

Why Dose Conservatively

LL-37 is a potent immune stimulator. Excessive dosing can cause significant local injection-site reactions, flu-like symptoms from cytokine release, potential aggravation of autoimmune conditions, and host-cell cytotoxicity at high concentrations.

Clinical wound-healing data also supports the principle that more is not necessarily better. A lower topical concentration of 0.5mg/mL outperformed a higher 1.6mg/mL concentration in wound healing, while still higher concentrations produced more inflammatory reactions. Start low and assess response before increasing.

LL-37 Reconstitution

The following example uses a standard 5mg vial with 2mL of bacteriostatic water.

5mg Vial

Vial Size

5mg

BAC Water

2mL

Concentration

2.5mg/mL

100mcg

4 units on an insulin syringe

200mcg

8 units on an insulin syringe

Reconstitution Calculator

Handling Notes

Mixing

Add BAC water to the vial.

Do Not

Do not shake aggressively.

Storage

Refrigerate after reconstitution.

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Users report using LL-37 for acute and chronic infections, including recurring sinus infections, Lyme disease co-infections, and chronic biofilm-associated infections.
For acute situations, some users report improvement in infection-related symptoms within the first week.
For chronic biofilm-associated issues, community reports commonly describe a 2 to 6 week timeline before meaningful changes are noticed.
Some users report better results when LL-37 is combined with conventional antibiotics, which is directionally consistent with laboratory synergy data.

Negative Reports

Injection-site redness, swelling, burning, stinging, and mild itching are the most consistently reported side effects and typically resolve within hours.
Some users report transient flu-like symptoms or worsening of autoimmune-related symptoms, especially at higher starting doses or in those with psoriasis or rosacea.

Stacking & Synergy

Potential LL-37 pairings and tracking context

LL-37 Stacking & Synergy

LL-37 + BPC-157

BPC-157 supports tissue healing through angiogenesis and repair signaling, while LL-37 provides antimicrobial protection and immune modulation. This pairing is commonly discussed when both tissue damage and infection risk are present.

LL-37 + Thymosin Alpha-1

Thymosin Alpha-1 primarily supports adaptive immunity and T-cell function, while LL-37 acts mainly through innate antimicrobial defense and innate immune-cell recruitment. The mechanisms are complementary.

LL-37 + Conventional Antibiotics

In vitro research shows synergy with beta-lactam antibiotics and vancomycin. LL-37 may disrupt bacterial membranes and improve antibiotic access to intracellular targets.

Medical Coordination

Anyone combining LL-37 with prescription antibiotics should coordinate with the prescribing clinician rather than altering or replacing prescribed therapy independently.

Free with login

Track in Journal

Track LL-37 with the markers that matter most for this compound.

Dose, timing, cycle day, and indication being tracked.
Temperature, fatigue, flu-like symptoms, and perceived immune response.
Injection-site reaction, inflammation, symptom changes, and adverse effects.

Start Tracking

Safety Notes

Side effects, contraindications, and precautions

LL-37 Side Effects

Topical wound-healing trials found LL-37 at 0.5 and 1.6mg/mL was generally well tolerated, with no serious adverse events attributed to the peptide at those concentrations. At 3.2mg/mL, some patients experienced ulcer necrosis or severe inflammatory reactions, which is why that concentration was not recommended.

Laboratory research also shows that LL-37 can become cytotoxic to host cells at sufficiently high concentrations. No published human safety data exists for injectable LL-37.

Published topical data does not establish the safety of injectable LL-37. Injectable use lacks a defined human safety profile.

Common User Reports

Injection-site redness, swelling, burning, stinging, or mild itching.
Local immune activation that usually resolves within several hours.
Flu-like symptoms during the first few days, including fatigue, body aches, low-grade fever, or malaise.

Potential Concerns

Potential worsening of psoriasis, rosacea, lupus, or other inflammatory and autoimmune conditions.
Possible aggravation of inflammatory bowel symptoms in some individuals.
Host-cell cytotoxicity at high concentrations.
Unknown long-term effects with chronic supplementation.

LL-37 Contraindications and Precautions

Do Not Use If You Have

Active autoimmune conditions where LL-37 dysregulation is implicated, including psoriasis, lupus, or rheumatoid arthritis.
Rosacea, because LL-37 is overexpressed in rosacea lesions and supplementation may worsen the condition.
Known hypersensitivity to LL-37 or any component of the preparation.

Use Caution With

History of autoimmune conditions, even if currently in remission.
Inflammatory bowel disease; monitor carefully for symptom changes.
Immunosuppressive medications, because LL-37 stimulates immune activity and may conflict with treatment goals.
Chronic inflammatory conditions.
Pregnancy or breastfeeding, because no safety data exists.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

We see LL-37 as a potent antimicrobial peptide. It can be very effective for stubborn infections, gut dysbiosis, or immune reset when nothing else seems to work. Lab rats around us have used it and the feedback has been very positive, with reports of strong results in clearing persistent issues.

We have not run LL-37 ourselves yet, but it looks very promising to keep on hand or in long-term freezer stock for when it’s needed. However, it’s strong medicine that requires careful, strategic use — not something for casual or daily application. Respect it as it can be powerful and almost too strong for some people.

Powerful when needed, but approach it with caution and clear purpose. Excellent tool in the right context, but use responsibly and in short cycles.